Loading company…
Zhongshan Hengsai develops individualized dendritic cell vaccines for tumor treatment.
Zhongshan Hengsai develops individualized dendritic cell therapeutic vaccines through its Eco-DCVax platform, targeting uses that include lymphoma, chronic viral infections, autoimmune diseases, and chronic active EB virus infection. Established in 2022 and based in Zhongshan, China, it closed a strategic funding round with Tasly Holding Group in December 2025.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign inWork at Zhongshan Hengsai Biotechnology Co., Ltd.? This is my company